NCT05577624已完成1 期
An Open-label Study to Evaluate the Drug-drug Interaction Effect of Rifampin, a CYP3A4 Inducer, on the Pharmacokinetics of AMG 510 in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Amgen
- 入组人数
- 14
- 试验地点
- 1
- 主要终点
- Area Under the Plasma Concentration-time Curve (AUC) from Time Zero to Time of Last Quantifiable Concentration (AUClast) of AMG 510
研究概览
简要总结
The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of AMG 510 alone and in combination with rifampin in healthy participants.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male participants or female participants, between 18 and 60 years of age (inclusive), at the time of Screening.
- •Body mass index, between 18 and 30 kg/m2 (inclusive), at the time of Screening.
- •Females of nonchildbearing potential
排除标准
- •Inability to swallow oral medication or history of malabsorption syndrome.
- •History of hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee) and in consultation with the Sponsor.
- •Poor peripheral venous access.
- •History or evidence, at Screening or Check in, of clinically significant disorder, condition, or disease not otherwise excluded that, in the opinion of the Investigator (or designee), would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.
研究组 & 干预措施
AMG 510 + Rifampin
Experimental
干预措施: AMG 510 (Drug)
AMG 510 + Rifampin
Experimental
干预措施: Rifampin (Drug)
结局指标
主要结局
Area Under the Plasma Concentration-time Curve (AUC) from Time Zero to Time of Last Quantifiable Concentration (AUClast) of AMG 510
时间窗: Days 1, 3 and 8
AUC from Time Zero to Infinity (AUCinf) of AMG 510
时间窗: Days 1, 3 and 8
Maximum Plasma Concentration (Cmax) of AMG 510
时间窗: Days 1, 3 and 8
次要结局
- AUCinf of AMG 510 Metabolite M24(Days 1, 3 and 8)
- AUClast of AMG 510 Metabolite M24(Days 1, 3 and 8)
- Cmax of AMG 510 Metabolite M24(Days 1, 3 and 8)
- Number of Participants with an Adverse Event (AE)(Day 1 to Day 20)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate the Drug-drug Interaction Effect of Itraconazole on the Pharmacokinetics (PK) of AMG 510 in Healthy ParticipantsHealthy ParticipantsNCT05568082Amgen14
已完成
1 期
Study to Evaluate the Drug-drug Interaction Effect of Omeprazole on the Pharmacokinetics (PK) of AMG 510 in Healthy ParticipantsHealthy ParticipantsNCT05581992Amgen14
已完成
1 期
Study to Evaluate the Drug-drug Interactions Between Metformin and AMG 510 in Healthy ParticipantsHealthy VolunteersNCT05550129Amgen13
已完成
1 期
A Study to Evaluate the Relative Bioavailability of AMG 510 Administered as Tablets and as a Water Dispersion in Healthy ParticipantsHealthy ParticipantsNCT05571163Amgen13
招募中
2 期
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia GravisGeneralized Myasthenia GravisNCT06392386argenx12